Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Income from Continuing Operations (2021 - 2023)

Historic Income from Continuing Operations for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.

  • Cullinan Therapeutics' Income from Continuing Operations rose 555.66% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24197.15%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
  • According to the latest figures from Q4 2023, Cullinan Therapeutics' Income from Continuing Operations is -$25.6 million, which was up 555.66% from -$39.2 million recorded in Q3 2023.
  • In the past 5 years, Cullinan Therapeutics' Income from Continuing Operations registered a high of $174.1 million during Q2 2022, and its lowest value of -$58.1 million during Q1 2023.
  • For the 3-year period, Cullinan Therapeutics' Income from Continuing Operations averaged around -$9.4 million, with its median value being -$25.2 million (2022).
  • Within the past 5 years, the most significant YoY rise in Cullinan Therapeutics' Income from Continuing Operations was 115885.39% (2022), while the steepest drop was 100627.2% (2022).
  • Cullinan Therapeutics' Income from Continuing Operations (Quarter) stood at -$34.2 million in 2021, then rose by 20.87% to -$27.1 million in 2022, then increased by 5.56% to -$25.6 million in 2023.
  • Its Income from Continuing Operations stands at -$25.6 million for Q4 2023, versus -$39.2 million for Q3 2023 and -$32.2 million for Q2 2023.